SCHEDULE: LSP 7 Boosts Evommune Stake to 14.7% in $10M Private Placement

LSP 7 Cooperatieve U.A. increased its beneficial ownership in Evommune, Inc. to 14.7% by purchasing 358,680 shares for nearly $10 million in a recent private placement.

Summary

• LSP 7 Cooperatieve U.A. (LSP 7) participated in a private placement by Evommune, Inc.
• LSP 7 purchased 358,680 shares of Common Stock at $27.88 per share, totaling $9,999,998.40.
• The private placement, which closed on February 17, 2026, involved the issuance of 4,494,279 shares to various institutional accredited investors.
• Following this transaction, LSP 7 beneficially owns 5,288,313 shares, representing approximately 14.7% of Evommune's outstanding Common Stock.
• Evommune, Inc. had 36,018,372 shares of Common Stock outstanding after the closing date.
• The funds for LSP 7's purchase came from capital contributions from its members.
• Evommune entered into a Registration Rights Agreement, obligating it to file a Form S-1 registration statement for the resale of these shares within 60 days of the closing date.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies successful capital infusion and continued investor confidence from a significant shareholder, which is crucial for a growth-oriented company.

Positives

• Evommune successfully completed a private placement, raising capital from institutional accredited investors.
• LSP 7, an existing significant investor, increased its stake, demonstrating continued confidence in Evommune.
• The private placement was priced at $27.88 per share, indicating a specific valuation for the new capital.

Negatives

• No explicit negatives are detailed in this filing.

Risks

• The Issuer is obligated to file a Form S-1 registration statement within 60 days of the closing date and use reasonable best efforts to have it declared effective within 90 days of filing, subject to extensions. Failure to meet these obligations could have consequences.
• The registration statement must remain effective until the shares are sold or can be resold under Rule 144 without restriction, implying an ongoing compliance burden for the Issuer.

Future Outlook

Evommune, Inc. is obligated to file a Form S-1 registration statement within 60 days of the February 17, 2026 closing date to register the resale of the newly issued shares and will use reasonable best efforts to have it declared effective within 90 days of its initial filing.

Industry Context

StockSavvy.ai notes that private placements with institutional investors like LSP 7 are a common method for biotechnology or early-stage companies like Evommune to raise capital, especially when public market conditions are volatile or when seeking strategic long-term investors. The participation of an existing significant shareholder like LSP 7 often signals continued investor confidence in the company's long-term prospects and strategic direction.

Comparison to Industry Standards

• The private placement price of $27.88 per share would need to be compared against Evommune's recent trading prices and valuations of comparable early-stage biotech companies to assess its attractiveness.
• The 14.7% stake held by LSP 7 is a substantial position, indicating a significant commitment, similar to major institutional holdings seen in companies like Moderna (Flagship Pioneering) or BioNTech (Strüngmann family offices) during their growth phases, where large investors maintain significant influence.
• The inclusion of a Registration Rights Agreement is standard practice in private placements to institutional investors, ensuring liquidity for their investment by facilitating future public resale.

Related Party Transactions

• LSP 7, a significant beneficial owner of Evommune, Inc. (14.7% stake), participated in the February 2026 private placement by purchasing 358,680 shares for $9,999,998.40. This transaction is considered a related party dealing due to LSP 7's substantial ownership and potential influence.

Stakeholder Impact

• Shareholders: Existing shareholders experience dilution from the issuance of new shares, but the capital raise strengthens the company's financial position. The registration rights agreement provides liquidity for the new investors, which could lead to future selling pressure.
• Company (Evommune, Inc.): Receives a significant capital infusion to fund operations and strategic initiatives.
• LSP 7: Increases its stake and influence in Evommune, Inc., with a clear path to liquidity for its investment via the registration rights.

Next Steps

• Evommune, Inc. is obligated to prepare and file a Form S-1 registration statement with the SEC within 60 days of February 17, 2026.
• Evommune, Inc. must use reasonable best efforts to have the Registration Statement declared effective as soon as possible, but no later than 90 days after its initial filing date.
• Evommune, Inc. must keep the Registration Statement effective until the shares are sold or can be resold pursuant to Rule 144 without restriction.

Key Dates

Recommendation

The filing indicates a successful capital raise and continued institutional investor confidence, which are positive. However, it's an amendment to a beneficial ownership report, not a comprehensive financial statement. Without full financial context, including the company's burn rate, specific use of proceeds, and recent operational performance, a definitive 'buy' or 'sell' is premature. The dilution from the private placement and potential future selling pressure from registered shares warrant a 'hold' until more comprehensive financial and operational updates are available.

Keywords

Evommune Inc., LSP 7, Private Placement, Schedule 13D/A, Common Stock, Institutional Investors, Registration Rights Agreement, Form S-1, Beneficial Ownership, Equity Financing